DK170800B1 - Substitueret benzimidazolderivat og fysiologisk acceptable salte og optiske enantiomerer heraf samt fremgangsmåde til fremstilling af samme, farmaceutisk præparat indeholdende derivatet, anvendelse af derivatet til fremstilling af et lægemiddel til hæmning af mavesyresekretionen hos pattedyr og til behandling af inflammatoriske mave-tarmkanallidelser hos pattedyr samt intermediære forbindelser til - Google Patents

Substitueret benzimidazolderivat og fysiologisk acceptable salte og optiske enantiomerer heraf samt fremgangsmåde til fremstilling af samme, farmaceutisk præparat indeholdende derivatet, anvendelse af derivatet til fremstilling af et lægemiddel til hæmning af mavesyresekretionen hos pattedyr og til behandling af inflammatoriske mave-tarmkanallidelser hos pattedyr samt intermediære forbindelser til Download PDF

Info

Publication number
DK170800B1
DK170800B1 DK122291A DK122291A DK170800B1 DK 170800 B1 DK170800 B1 DK 170800B1 DK 122291 A DK122291 A DK 122291A DK 122291 A DK122291 A DK 122291A DK 170800 B1 DK170800 B1 DK 170800B1
Authority
DK
Denmark
Prior art keywords
derivative
compound
mammals
preparing
cyclopropylmethoxy
Prior art date
Application number
DK122291A
Other languages
Danish (da)
English (en)
Other versions
DK122291A (da
DK122291D0 (da
Inventor
Arne Elof Braendstroem
Per Lennart Lindberg
Gunnel Elisabeth Sunden
Original Assignee
Haessle Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Haessle Ab filed Critical Haessle Ab
Publication of DK122291D0 publication Critical patent/DK122291D0/da
Publication of DK122291A publication Critical patent/DK122291A/da
Application granted granted Critical
Publication of DK170800B1 publication Critical patent/DK170800B1/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/28Sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK122291A 1988-12-22 1991-06-21 Substitueret benzimidazolderivat og fysiologisk acceptable salte og optiske enantiomerer heraf samt fremgangsmåde til fremstilling af samme, farmaceutisk præparat indeholdende derivatet, anvendelse af derivatet til fremstilling af et lægemiddel til hæmning af mavesyresekretionen hos pattedyr og til behandling af inflammatoriske mave-tarmkanallidelser hos pattedyr samt intermediære forbindelser til DK170800B1 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE8804629 1988-12-22
SE19888804629A SE8804629D0 (sv) 1988-12-22 1988-12-22 New therapeutically active compounds
PCT/SE1989/000740 WO1990006925A1 (en) 1988-12-22 1989-12-20 New therapeutically active compound and a process for its preparation
SE8900740 1989-12-20

Publications (3)

Publication Number Publication Date
DK122291D0 DK122291D0 (da) 1991-06-21
DK122291A DK122291A (da) 1991-06-24
DK170800B1 true DK170800B1 (da) 1996-01-22

Family

ID=20374310

Family Applications (1)

Application Number Title Priority Date Filing Date
DK122291A DK170800B1 (da) 1988-12-22 1991-06-21 Substitueret benzimidazolderivat og fysiologisk acceptable salte og optiske enantiomerer heraf samt fremgangsmåde til fremstilling af samme, farmaceutisk præparat indeholdende derivatet, anvendelse af derivatet til fremstilling af et lægemiddel til hæmning af mavesyresekretionen hos pattedyr og til behandling af inflammatoriske mave-tarmkanallidelser hos pattedyr samt intermediære forbindelser til

Country Status (32)

Country Link
US (2) US5008278A (zh)
EP (1) EP0449940B1 (zh)
JP (1) JP2793906B2 (zh)
KR (1) KR910700249A (zh)
CN (1) CN1028231C (zh)
AR (1) AR248136A1 (zh)
AT (1) ATE127799T1 (zh)
AU (1) AU634741B2 (zh)
BG (1) BG60102B2 (zh)
CA (1) CA2005986C (zh)
DD (2) DD296078A5 (zh)
DE (1) DE68924273T2 (zh)
DK (1) DK170800B1 (zh)
EG (1) EG19303A (zh)
FI (2) FI913035A0 (zh)
GR (1) GR1002252B (zh)
HR (1) HRP920831A2 (zh)
HU (2) HU205927B (zh)
IE (1) IE894048L (zh)
IL (1) IL92798A0 (zh)
LT (2) LT3914B (zh)
LV (1) LV10187B (zh)
NZ (1) NZ231872A (zh)
PH (1) PH27400A (zh)
PL (1) PL161150B1 (zh)
PT (1) PT92648B (zh)
RO (1) RO110494B1 (zh)
RU (2) RU2073676C1 (zh)
SE (1) SE8804629D0 (zh)
WO (1) WO1990006925A1 (zh)
YU (1) YU46806B (zh)
ZA (2) ZA899795B (zh)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ244301A (en) * 1991-09-20 1994-08-26 Merck & Co Inc Preparation of 2-pyridylmethylsulphinylbenzimidazole and pyridoimidazole derivatives from the corresponding sulphenyl compounds
TNSN95063A1 (fr) * 1994-05-27 1996-02-06 Astra Ab Nouveaux benzimidazoles substitues
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
ATE414509T1 (de) * 1994-07-08 2008-12-15 Astrazeneca Ab Aus vielen einzeleinheiten zusammengesetzte tablettierte dosisform
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
SE9500478D0 (sv) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
DE19758573C2 (de) * 1997-11-26 2001-03-01 Implex Hear Tech Ag Fixationselement für ein implantierbares Mikrofon
KR100627614B1 (ko) * 1998-04-20 2006-09-25 에자이 가부시키가이샤 안정화된 벤즈이미다졸계 화합물 함유 조성물로 이루어지는 의약제제
TWI243672B (en) 1999-06-01 2005-11-21 Astrazeneca Ab New use of compounds as antibacterial agents
ATE369857T1 (de) 1999-10-20 2007-09-15 Eisai R&D Man Co Ltd Methode zur stabilisierung von benzimidazol- verbindungen
SE0000774D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
SE0101379D0 (sv) 2001-04-18 2001-04-18 Diabact Ab Komposition som hämmar utsöndring av magsyra
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
SE0102993D0 (sv) 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
US20040006111A1 (en) * 2002-01-25 2004-01-08 Kenneth Widder Transmucosal delivery of proton pump inhibitors
CA2480358A1 (en) * 2002-03-26 2003-10-09 Dr. Reddy's Laboratories Limited Crystalline forms of rabeprazole sodium
SE0203065D0 (sv) 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
US20040248942A1 (en) * 2003-02-20 2004-12-09 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
WO2005007115A2 (en) * 2003-07-18 2005-01-27 Santarus, Inc. Pharmaceutical composition for inhibiting acid secretion
US20050031700A1 (en) * 2003-07-18 2005-02-10 Sanatarus, Inc. Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders
US8993599B2 (en) * 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
EP1708684A2 (en) 2003-09-26 2006-10-11 Alza Corporation Drug coating providing high drug loading and methods for providing the same
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
US8815916B2 (en) * 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) * 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8541026B2 (en) 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
US7981908B2 (en) 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
US7803817B2 (en) 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
CA2658804A1 (en) 2006-07-25 2008-01-31 Vecta Ltd. Compositions and methods for inhibiting gastric acid secretion using derivatives of small dicarboxylic acids in combination with ppi
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
CA2736547C (en) 2008-09-09 2016-11-01 Pozen Inc. Method for delivering a pharmaceutical composition to patient in need thereof
AU2010263304A1 (en) 2009-06-25 2012-02-02 Astrazeneca Ab Method for treating a patient at risk for developing an NSAID-associated ulcer
WO2011080500A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
EP2519229A2 (en) 2009-12-29 2012-11-07 Novartis AG New pharmaceutical dosage form for the treatment of gastric acid-related disorders
WO2011080502A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
EP2601947A1 (en) 2011-12-05 2013-06-12 Abo Bakr Mohammed Ali Al-Mehdar Fixed-dose combination for treatment of helicobacter pylori associated diseases
UA115139C2 (uk) 2011-12-28 2017-09-25 Поузен Інк. Спосіб доставки фармацевтичної композиції, яка містить омепразол й ацетилсаліцилову кислоту, пацієнту

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US428098A (en) 1890-05-20 Electric railway
US727150A (en) 1902-06-18 1903-05-05 Peter Paul Keller Adjustable hanger for incandescent lamps.
SE418966B (sv) * 1974-02-18 1981-07-06 Haessle Ab Analogiforfarande for framstellning av foreningar med magsyrasekretionsinhiberande verkan
SE416649B (sv) * 1974-05-16 1981-01-26 Haessle Ab Forfarande for framstellning av foreningar som paverkar magsyrasekretionen
IN148930B (zh) * 1977-09-19 1981-07-25 Hoffmann La Roche
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
US4359465A (en) * 1980-07-28 1982-11-16 The Upjohn Company Methods for treating gastrointestinal inflammation
CH644116A5 (de) * 1980-08-21 1984-07-13 Hoffmann La Roche Imidazolderivate.
DE3215503A1 (de) 1982-04-26 1983-11-03 Zängl GmbH, 8000 München Elektrisch beheiztes schneidgeraet
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
HU195220B (en) * 1983-05-03 1988-04-28 Byk Gulden Lomberg Chem Fqb Process for production of new fluor-alkoxi-benzimidasole-derivatives and medical compositions containig them
JPS6150979A (ja) * 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
JPS6150978A (ja) * 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
AU568441B2 (en) * 1984-09-24 1987-12-24 Upjohn Company, The 2-(pyridylalkenesulfinyl) benzimidazole derivatives
US4738975A (en) * 1985-07-02 1988-04-19 Takeda Chemical Industries, Ltd. Pyridine derivatives, and use as anti-ulcer agents
JPS6261978A (ja) * 1985-09-12 1987-03-18 Otsuka Pharmaceut Co Ltd 5−フルオロ−1h−ベンズイミダゾ−ル誘導体
SE8505112D0 (sv) * 1985-10-29 1985-10-29 Haessle Ab Novel pharmacological compounds
JPS62201884A (ja) * 1986-02-28 1987-09-05 Tokyo Tanabe Co Ltd ベンズイミダゾール誘導体及びその製造法
FI90544C (fi) * 1986-11-13 1994-02-25 Eisai Co Ltd Menetelmä lääkeaineina käyttökelpoisten 2-pyridin-2-yyli-metyylitio- ja sulfinyyli-1H-bensimidatsolijohdannaisten valmistamiseksi
NZ222495A (en) * 1986-11-21 1991-04-26 Haessle Ab Benzimidazole derivatives and pharmaceutical compositions
FI96860C (fi) * 1987-06-17 1996-09-10 Eisai Co Ltd Analogiamenetelmä lääkeaineena käytettävän pyridiinijohdannaisen valmistamiseksi
DE3722810A1 (de) * 1987-07-10 1989-01-19 Hoechst Ag Substituierte benzimidazole, verfahren zu deren herstellung, diese enthaltende pharmazeutische zubereitungen und deren verwendung
DK171989B1 (da) * 1987-08-04 1997-09-08 Takeda Chemical Industries Ltd Fremgangsmåde til fremstilling af 2-(2-pyridylmethylsulfinyl)-benzimidazoler
JPH0676323B2 (ja) * 1987-08-28 1994-09-28 東京田辺製薬株式会社 抗潰瘍剤

Also Published As

Publication number Publication date
CA2005986A1 (en) 1990-06-22
WO1990006925A1 (en) 1990-06-28
FI913035A0 (fi) 1991-06-20
LV10187B (en) 1995-04-20
ZA899795B (en) 1990-08-29
AU634741B2 (en) 1993-03-04
ATE127799T1 (de) 1995-09-15
IE894048L (en) 1990-06-22
FI954768A0 (fi) 1995-10-06
RU2073676C1 (ru) 1997-02-20
DD296079A5 (de) 1991-11-21
DE68924273D1 (de) 1995-10-19
PL161150B1 (en) 1993-05-31
JPH04502461A (ja) 1992-05-07
PT92648A (pt) 1990-06-29
US5008278A (en) 1991-04-16
CA2005986C (en) 1999-08-03
RU2042673C1 (ru) 1995-08-27
DK122291A (da) 1991-06-24
GR1002252B (en) 1996-04-23
BG60102B2 (bg) 1993-10-29
SE8804629D0 (sv) 1988-12-22
DK122291D0 (da) 1991-06-21
YU242689A (en) 1991-04-30
KR910700249A (ko) 1991-03-14
HU205927B (en) 1992-07-28
HRP920831A2 (en) 1995-12-31
DE68924273T2 (de) 1996-02-15
CN1028231C (zh) 1995-04-19
RO110494B1 (ro) 1996-01-30
EG19303A (en) 1994-11-30
HU901084D0 (en) 1991-09-30
ZA899794B (en) 1990-08-29
LT3980B (en) 1996-06-25
LTIP1726A (en) 1995-07-25
US5039808A (en) 1991-08-13
GR890100838A (el) 1991-03-15
CN1043713A (zh) 1990-07-11
DD296078A5 (de) 1991-11-21
NZ231872A (en) 1992-03-26
HU205926B (en) 1992-07-28
IL92798A0 (en) 1990-09-17
LV10187A (lv) 1994-10-20
JP2793906B2 (ja) 1998-09-03
HUT57202A (en) 1991-11-28
PT92648B (pt) 1995-09-12
PH27400A (en) 1993-06-21
YU46806B (sh) 1994-06-10
LTIP1721A (en) 1995-07-25
FI954768A (fi) 1995-10-06
AR248136A1 (es) 1995-06-30
LT3914B (en) 1996-04-25
EP0449940A1 (en) 1991-10-09
AU4817590A (en) 1990-07-10
EP0449940B1 (en) 1995-09-13

Similar Documents

Publication Publication Date Title
DK170800B1 (da) Substitueret benzimidazolderivat og fysiologisk acceptable salte og optiske enantiomerer heraf samt fremgangsmåde til fremstilling af samme, farmaceutisk præparat indeholdende derivatet, anvendelse af derivatet til fremstilling af et lægemiddel til hæmning af mavesyresekretionen hos pattedyr og til behandling af inflammatoriske mave-tarmkanallidelser hos pattedyr samt intermediære forbindelser til
AP253A (en) Dialkoxy-pyridinyl-benzimidazole derivatives process for their preparation and thei phamaceutical use.
IE904249A1 (en) Therapeutically active chloro substituted benzimidazoles,¹processes for their preparation as well as their use
CZ279772B6 (cs) Substituované benzimidazoly, způsob jejich výroby a jejich farmaceutické použití
DK170801B1 (da) Terapeutisk aktivt, substitueret benzimidazolderivat og fysiologisk acceptable salte og optiske enantiomerer heraf samt fremgangsmåde til fremstilling af samme, farmaceutisk præparat indeholdende benzimidazolderivatet, anvendelse af derivatet til fremstilling af et lægemiddel til hæmning af mavesyresekretionen hos pattedyr og til behandling af inflammatoriske mavetarmkanallidelser hos pattedyr sam
CA2005980C (en) Benzimidazole derivative with gastric acid inhibitory effect and process for its preparation
IE904248A1 (en) Therapeutically active fluoro substituted benzimidazoles,¹processes for their preparation as well as their use

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
PBP Patent lapsed